High-dose ifosfamide as second-or third-line chemotherapy in refractory bone and soft tissue sarcoma patients

Oncology

Volumn 80, Issue 3-4, 2011, Pages 257-261

  Lee, Soo Hyeon ^a   Chang, Myung Hee ^a   Baek, Kyung Kee ^a   Han, Boram ^a   Lim, Taekyu ^a   Lee, Jeeyun ^a   Park, Joon Oh ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Chemotherapy; High dose ifosfamide; Sarcoma; Second line

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BRAIN DISEASE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MALE; METASTASIS; NEUTROPENIA; OSTEOSARCOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SECOND LINE CHEMOTHERAPY; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; THIRD LINE CHEMOTHERAPY; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IFOSFAMIDE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPENIA; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SARCOMA; SOFT TISSUE NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79959853824     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000328795     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Skubitz KM, D'Adamo DR: Sarcoma. Mayo Clin Proc 2007; 82: 1409-1432. (Pubitemid 350060138)
3. Lorigan P, Verweij J, Papai Z, Rodenhuis S, Le Cesne A, Leahy MG, Radford JA, Van Glabbeke MM, Kirkpatrick A, Hogendoorn PC, Blay JY: Phase iii trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a european organisation for research and treatment of cancer soft tissue and bone sarcoma group study. J Clin Oncol 2007; 25: 3144-3150. (Pubitemid 47218064)
4. Tascilar M, Loos WJ, Seynaeve C, Verweij J, Sleijfer S: The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas. Oncologist 2007; 12: 1351-1360. (Pubitemid 350232609)
5. Nielsen OS, Judson I, van Hoesel Q, le Cesne A, Keizer HJ, Blay JY, van Oosterom A, Radford JA, Svancarova L, Krzemienlecki K, Hermans C, van Glabbeke M, Oosterhuis JW, Verweij J: Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase ii study of the eortc soft tissue and bone sarcoma group. Eur J Cancer 2000; 36: 61-67. (Pubitemid 30035345)
6. Palumbo R, Palmeri S, Antimi M, Gatti C, Raffo P, Villani G, Toma S: Phase ii study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. Ann Oncol 1997; 8: 1159-1162. (Pubitemid 27521226)
7. Tursz T: High-dose ifosfamide in the treatment of advanced soft tissue sarcomas. Semin Oncol 1996; 23: 34-39. (Pubitemid 26270049)
8. De Pas T, De Braud F, Orlando L, Nole F, Munzone E, Zampino MG, Fazio N, Aapro MS, Goldhirsch A: High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible Ann Oncol 1998; 9: 917-919. (Pubitemid 28440453)
9. Le Cesne A, Antoine E, Spielmann M, Le Chevalier T, Brain E, Toussaint C, Janin N, Kayitalire L, Fontaine F, Genin J, et al: Highdose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995; 13: 1600-1608.
10. Delaloge S, Yovine A, Taamma A, Riofrio M, Brain E, Raymond E, Cottu P, Goldwasser F, Jimeno J, Misset JL, Marty M, Cvitkovic E: Ecteinascidin-743:A marine-derived compound in advanced, pretreated sarcoma patients-preliminary evidence of activity. J Clin Oncol 2001; 19: 1248-1255. (Pubitemid 32202527)
11. Le Cesne A, Blay JY, Judson I, Van Oosterom A, Verweij J, Radford J, Lorigan P, Rodenhuis S, Ray-Coquard I, Bonvalot S, Collin F, Jimeno J, Di Paola E, Van Glabbeke M, Nielsen OS: Phase ii study of et-743 in advanced soft tissue sarcomas: a european organisation for the research and treatment of cancer (eortc) soft tissue and bone sarcoma group trial. J Clin Oncol 2005; 23: 576-584. (Pubitemid 46224235)
12. Yovine A, Riofrio M, Blay JY, Brain E, Alexandre J, Kahatt C, Taamma A, Jimeno J, Martin C, Salhi Y, Cvitkovic E, Misset JL: Phase ii study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004; 22: 890-899. (Pubitemid 41103601)
13. Buesa JM, Mouridsen HT, van Oosterom AT, Verweij J, Wagener T, Steward W, Poveda A, Vestlev PM, Thomas D, Sylvester R: Highdose dtic in advanced soft-tissue sarcomas in the adult. A phase ii study of the e.O.R.T.C. Soft tissue and bone sarcoma group. Ann Oncol 1991; 2: 307-309.
14. Merimsky O, Meller I, Flusser G, Kollender Y, Issakov J, Weil-Ben-Arush M, Fenig E, Neuman G, Sapir D, Ariad S, Inbar M: Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase ii study. Cancer Chemother Pharmacol 2000; 45: 177-181. (Pubitemid 30090250)
15. Zucali PA, Bertuzzi A, Parra HJ, Campa gnoli E, Quagliuolo V, Santoro A: The 'old drug' dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas. Invest New Drugs 2008; 26: 175-181. (Pubitemid 351357711)
16. Chou AJ, Merola PR, Wexler LH, Gorlick RG, Vyas YM, Healey JH, LaQuaglia MP, Huvos AG, Meyers PA: Treatment of osteosarcoma at first recurrence after contemporary therapy: the memorial sloan-kettering cancer center experience. Cancer 2005; 104: 2214-2221. (Pubitemid 41579969)
17. van Oosterom AT, Mouridsen HT, Nielsen OS, Dombernowsky P, Krzemieniecki K, Judson I, Svancarova L, Spooner D, Hermans C, Van Glabbeke M, Verweij J: Results of randomised studies of the eortc soft tissue and bone sarcoma group (stbsg) with two different ifosfamide regimens in first-and secondline chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer 2002; 38: 2397-2406. (Pubitemid 35387492)
18. Sutton GP, Blessing JA, Barrett RJ, McGehee R: Phase ii trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a gynecologic oncology group study. Am J Obstet Gynecol 1992; 166: 556-559.
19. Rosen G, Forscher C, Lowenbraun S, Eilber F, Eckardt J, Holmes C, Fu YS: Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer 1994; 73: 2506-2511. (Pubitemid 24155525)
20. Haldar M, Randall RL, Capecchi MR: Synovial sarcoma: From genetics to genetic-based animal modeling. Clin Orthop Relat Res 2008; 466: 2156-2167.
21. Wagner LM, McAllister N, Goldsby RE, Rausen AR, McNall-Knapp RY, McCarville MB, Albritton K: Temozolomide and intravenous irinotecan for treatment of advanced ewing sarcoma. Pediatr Blood Cancer 2007; 48: 132-139. (Pubitemid 44958268)
22. DiMaggio JR, Brown R, Baile WF, Schapira D: Hallucinations and ifosfamide-induced neurotoxicity. Cancer 1994; 73: 1509-1514. (Pubitemid 24072562)
23. Salloum E, Flamant F, Ghosn M, Taleb N, Akatchereian C: Irreversible encephalopathy with ifosfamide/mesna. J Clin Oncol 1987; 5: 1303-1304.
24. Nicolao P, Giometto B: Neurological toxicity of ifosfamide. Oncology 2003; 65(suppl 2): 11-16. (Pubitemid 37346724)
25. Antman KH, Elias A, Ryan L: Ifosfamide and mesna: Response and toxicity at standardand high-dose schedules. Semin Oncol 1990; 17: 68-73. (Pubitemid 20176951)
26. Van Glabbeke M, Verweij J, Judson I, Nielsen OS: Progression-free rate as the principal end-point for phase ii trials in soft-tissue sarcomas. Eur J Cancer 2002; 38: 543-549. (Pubitemid 34185394)